Your browser doesn't support javascript.
loading
Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study.
Espíndola, R; Vella, V; Benito, N; Mur, I; Tedeschi, S; Zamparini, E; Hendriks, J G E; Sorlí, L; Murillo, O; Soldevila, L; Scarborough, M; Scarborough, C; Kluytmans, J; Ferrari, M C; Pletz, M W; McNamara, I; Escudero-Sanchez, R; Arvieux, C; Batailler, C; Dauchy, F-A; Liu, W-Y; Lora-Tamayo, J; Praena, J; Ustianowski, A; Cinconze, E; Pellegrini, M; Bagnoli, F; Rodríguez-Baño, J; Del-Toro-López, M-D.
Afiliación
  • Espíndola R; Infectious Diseases and Microbiology Clinical Unit, Hospital Universitario Virgen Macarena, Seville, Spain; Biomedicine Institute of Sevilla (IBiS)/CSIC, Seville, Spain.
  • Vella V; GlaxoSmithKline (GSK), Siena, Italy.
  • Benito N; Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau/Sant Pau Institute for Biomedical Research, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Sa
  • Mur I; Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau/Sant Pau Institute for Biomedical Research, Barcelona, Spain.
  • Tedeschi S; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Infectious Diseases Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
  • Zamparini E; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Hendriks JGE; Department of Orthopaedic Surgery & Trauma, Máxima MC, Eindhoven, The Netherlands.
  • Sorlí L; Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain.
  • Murillo O; Department of Infectious Diseases, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain.
  • Soldevila L; Department of Infectious Diseases, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain.
  • Scarborough M; Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Scarborough C; Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Kluytmans J; Department of Infection Control, Amphia Hospital, Breda, The Netherlands; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Ferrari MC; Prosthetic-Joint Replacement Unit, Humanitas Research Hospital, Milano, Italy.
  • Pletz MW; Center for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.
  • McNamara I; Department of Orthopaedics, Norfolk and Norwich University Hospital, Norwich, UK.
  • Escudero-Sanchez R; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Infectious Diseases, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Arvieux C; Department of Infectious Diseases, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Batailler C; Orthopedic Surgery Department, Croix Rousse Hospital, Lyon, France.
  • Dauchy FA; Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
  • Liu WY; Department of Orthopaedic Surgery & Trauma, Máxima MC, Eindhoven, The Netherlands; Department of Orthopaedic Surgery & Trauma, Catharina Hospital, Eindhoven, The Netherlands.
  • Lora-Tamayo J; Department of Internal Medicine (CIBERINFEC-CIBER de Enfermedades Infecciosas), Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Praena J; Clinical Unit of Infectious Diseases and Microbiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Ustianowski A; Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK.
  • Cinconze E; GlaxoSmithKline (GSK), Siena, Italy.
  • Pellegrini M; GlaxoSmithKline (GSK), Siena, Italy.
  • Bagnoli F; GlaxoSmithKline (GSK), Siena, Italy.
  • Rodríguez-Baño J; Infectious Diseases and Microbiology Clinical Unit, Hospital Universitario Virgen Macarena, Seville, Spain; Biomedicine Institute of Sevilla (IBiS)/CSIC, Seville, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; D
  • Del-Toro-López MD; Infectious Diseases and Microbiology Clinical Unit, Hospital Universitario Virgen Macarena, Seville, Spain; Biomedicine Institute of Sevilla (IBiS)/CSIC, Seville, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; D
J Hosp Infect ; 142: 9-17, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37797656
BACKGROUND: The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres. METHODS: This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables. RESULTS: The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI. CONCLUSIONS: This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Estafilocócicas / Infecciones Relacionadas con Prótesis / Artroplastia de Reemplazo de Cadera Tipo de estudio: Incidence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Hosp Infect Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Estafilocócicas / Infecciones Relacionadas con Prótesis / Artroplastia de Reemplazo de Cadera Tipo de estudio: Incidence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Hosp Infect Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido